The Experience of a Multidisciplinary Clinic in the Management of Early-Stage Breast Cancer Patients Receiving Trastuzumab Therapy: An Observational Study

Table 4

Treatment outcomes.

	Early stage breast cancer patients
	Chemotherapy
Chemotherapy completion
(i) Complete	45 (93.7%)
(ii) Discontinued (non cardiotoxicity)	1 (2.1%)
(iii) Discontinued (Patient choice)	2 (4.2%)
Chemotherapy cycle delays
(i) Cardiotoxicity	1 (2.1%)
(ii) Completion post delays	1 (100%)
Trastuzumab
Trastuzumab completion
(i) Complete	37 (77.1%)
(ii) Discontinued (cardiotoxicity)	7 (14.6%)
(iii) Discontinued (non cardiotoxicity)	2 (4.2%)
(iv) Discontinued (Patient choice)	2 (4.2%)
≥90% trastuzumab completion (16–18; cycles)	39 (81.3%)
Trastuzumab cycle delays
(i) Cardiotoxicity	16 (33.3%)
(ii) Completion post delays	12 (75%)
Cardiac medication	12 (25%)
(i) ACE inhibitor	10 (83.3%)
(ii) Beta blocker	6 (50%)
(iii) Other cardiac drugs	2 (16.7%)